Annual report [Section 13 and 15(d), not S-K Item 405]

Business Combination - Intangible Assets Acquired (Details)

v3.26.1
Business Combination - Intangible Assets Acquired (Details) - USD ($)
3 Months Ended 12 Months Ended
Dec. 31, 2024
Dec. 31, 2025
Dec. 31, 2024
Indefinite-Lived Intangible Assets [Roll Forward]      
Impairment   $ 0 $ 0
Goodwill      
Combination Date Fair Value   11,812,476  
Impairment   0 0
Carrying Value $ 11,812,476 12,401,118 11,812,476
Pharmagesic      
Indefinite-Lived Intangible Assets [Roll Forward]      
Combination Date Fair Value 69,500,000 65,710,527  
Translation Adj (3,789,473) 3,274,499  
Carrying Value 65,710,527 68,985,026 65,710,527
Goodwill      
Combination Date Fair Value 12,493,727 11,812,476  
Translation Adj (681,251) 588,642  
Carrying Value 11,812,476 12,401,118 11,812,476
Pharmagesic | Halneuron for Cancer Related Pain      
Indefinite-Lived Intangible Assets [Roll Forward]      
Combination Date Fair Value 59,900,000 56,633,965  
Translation Adj (3,266,035) 2,822,194  
Carrying Value 56,633,965 59,456,159 56,633,965
Pharmagesic | Halneuron for Chemotherapy Induced Neuropathic Pain      
Indefinite-Lived Intangible Assets [Roll Forward]      
Combination Date Fair Value 9,600,000 9,076,562  
Translation Adj (523,438) 452,305  
Carrying Value $ 9,076,562 $ 9,528,867 $ 9,076,562